News Search

18 Feb 2015 | Other

Actavis Announces Intention to Adopt "Allergan" Corporate Name

Actavis plc (NYSE: ACT) today announced that it will adopt a new corporate name - Allergan - following the anticipated successful completion of the acquisition of Allergan, Inc. The Company said that it intends to use the Allergan name as its corporate name and for its global branded pharmaceutical portfolio, and will retain the Actavis name for select geographic regions and product portfolios. The change in corporate name would be subject to approval by Actavis' shareholders at its Annual General Meeting later this year.

"The pending combination of Actavis and Allergan will create a dynamic new breed of company - a leader in Growth Pharma. By adopting the Allergan name for the corporation we will ensure that our corporate identity reflects the dramatic evolution of our company within the pharmaceutical industry," said Brent Saunders, CEO and President of Actavis.

"For more than 65 years, the Allergan name has represented innovation in branded pharmaceuticals, a commitment to bringing the best medicine to life and a strong partnership with physicians. The Actavis name has represented our global commitment to leadership in generic, branded generic and OTC pharmaceuticals and to increased access to more affordable prescription medicine for consumers around the world. Together, our combined company will be equally focused on developing new medicines that meet unmet medical needs in critical therapeutic categories, as well as increasing global access to high quality, affordable medicines.

"Using the Allergan name for our combined brand product portfolios recognizes this powerful heritage. We are convinced that the Allergan name will provide an umbrella of exceptional brand equity for an expanded and even more relevant global brand pharmaceutical portfolio. And it will communicate unequivocally what we stand for in the brand pharmaceutical space."


Full story on Allergan.com  
Media Contacts
Mark Marmur
Global Corporate Media Relations
Tel: +1 (862) 261 7558
Fran DeSena
U.S. Product Media Relations
Tel: +1 (201) 427-8762

Karina Calzadilla
Investor Relations
Tel: +1 862 261 7488